Cue Historical Income Statement
| CUE Stock | USD 1.89 0.02 1.07% |
Historical analysis of Cue Biopharma income statement accounts such as Interest Expense of 1.2 M, Selling General Administrative of 11.7 M or Total Revenue of 3.6 M can show how well Cue Biopharma performed in making a profits. Evaluating Cue Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cue Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cue Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cue Biopharma is a good buy for the upcoming year.
Cue |
About Cue Income Statement Analysis
Cue Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cue Biopharma shareholders. The income statement also shows Cue investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cue Biopharma Income Statement Chart
Cue Biopharma Income Statement is one of the three primary financial statements used for reporting Cue's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cue Biopharma revenue and expense. Cue Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Cue Biopharma's Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 1.3 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cue Biopharma. It is also known as Cue Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Cue Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 1.3 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 45.9K | 928.2K | 2.7M | 2.8M | Net Interest Income | 45.9K | 214.4K | 1.4M | 1.5M |
Cue Biopharma income statement Correlations
Click cells to compare fundamentals
Cue Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cue Biopharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.2M | 1.1M | (1.8M) | 2.5M | 3.4M | 3.6M | |
| Interest Expense | 5.6M | 463.9K | 1.7M | 713.8K | 1.2M | 1.2M | |
| Selling General Administrative | 12.7M | 14.7M | 17.3M | 16.2M | 16.7M | 11.7M | |
| Total Revenue | 3.5M | 3.2M | 14.9M | 1.2M | 5.5M | 3.6M | |
| Gross Profit | 3.5M | (30.4M) | 14.9M | (560.8K) | 2.1M | 2.2M | |
| Other Operating Expenses | 40.2M | 48.2M | 58.7M | 54.7M | 57.5M | 40.6M | |
| Operating Income | (36.8M) | (45.0M) | (43.7M) | (53.2M) | (52.0M) | (54.6M) | |
| Net Income From Continuing Ops | (36.7M) | (44.8M) | (44.2M) | (53.0M) | (50.7M) | (53.3M) | |
| Ebit | (36.8M) | (45.0M) | (43.7M) | (53.2M) | (52.0M) | (54.6M) | |
| Research Development | 27.5M | 33.5M | 41.3M | 38.6M | 40.3M | 28.8M | |
| Ebitda | (31.6M) | (44.0M) | (45.5M) | (50.8M) | (48.6M) | (51.0M) | |
| Cost Of Revenue | 27.5M | 33.5M | (1.8M) | 1.8M | 3.4M | 3.3M | |
| Total Operating Expenses | 40.2M | 48.2M | 58.7M | 54.7M | 54.0M | 40.2M | |
| Income Before Tax | (36.3M) | (44.6M) | (43.7M) | (53.0M) | (50.7M) | (53.3M) | |
| Total Other Income Expense Net | 483K | 463.9K | 45.9K | 214.4K | 1.3M | 1.3M | |
| Net Income Applicable To Common Shares | (36.7M) | (44.8M) | (44.2M) | (53.0M) | (47.7M) | (50.1M) | |
| Net Income | (36.7M) | (44.8M) | (44.2M) | (52.8M) | (50.7M) | (53.3M) | |
| Income Tax Expense | 412K | 206.3K | 495K | (214.4K) | (246.6K) | (234.3K) | |
| Net Interest Income | 418.7K | 463.9K | 45.9K | 214.4K | 1.4M | 1.5M | |
| Interest Income | 418.7K | 463.9K | 45.9K | 928.2K | 2.7M | 2.8M | |
| Reconciled Depreciation | 5.2M | 1.1M | (1.8M) | 1.8M | 3.4M | 3.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share 0.149 | Quarterly Revenue Growth 8.182 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.